Home » Clinical Trials » Anxiety Disorders
Clinical Trial Details
Research Study Summary
A clinical trial to evaluate treatments using Pregabalin and Pregabalin Placebo Capsules for patients with Schizophrenia or Anxiety-comorbidity to Schizophrenia
Research Study Title
Pregablin for Anxiety-comorbidity in Patients With Schizophrenia - a Double-blinded Randomized Placebo Controlled Study
The PACS study aims to investigate the efficacy and tolerability of pregabalin for
schizophrenic patients that suffer from comorbid anxiety.
The study design is an 8 week flexible dosage, randomized placebo controlled.
The study population is patients diagnosed with ICD-10 schizophrenia and age 18-65. Patients
are recruited from outpatient clinics from entire Denmark.
To Learn more
Both Male and Female
Both Male and Female ages 18 Years to 65 Years
Ages 18-65 years
An ICD-10 schizophrenia diagnosis F20.0-20.3 or F20.9
Stable dosage of psychotropic 4 weeks before inclusion
Hamilton Anxiety Scale total score > 15
Positive and Negative Syndrome Scale for Schizophrenia total score < 70
The Calgary Depression Scale for Schizophrenia total score < 10
Fertile women: Contraception during the trial
S-creatinin within normal reference range
Signed informed consent and power of attorney
Significant substance abuse
QTc > 480 milliseconds
Severe dysregulated diabetes
For women: Pregnancy or breast-feeding
Confinement in accordance with the Danish Law of Psychiatry
Known hypersensitivity or allergic reaction to the active ingredient of the drug
Site Locations (1)
||Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Schizophrenia
Jimmi Nielsen, M.D
Jimmi Nielsen, M.D.
NCT ID: NCT01496690
Date Last Changed: February 26, 2015
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.